Publications

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
J Clin Oncol 2018 Feb 2:JCO2017773994. Epub 2018 Feb 2.
Margaretha G.M. Roemer, Robert A. Redd, Fathima Zumla Cader, Christine J. Pak, Sara Abdelrahman, Jing Ouyang, Philippe Armand, Donna S. Neuberg, and Margaret A. Shipp, Dana-Farber Cancer Institute; Geraldine S. Pinkus, Azra H. Ligon, and Scott J. Rodig, Brigham and Women's Hospital, Boston, MA; Margaretha G.M. Roemer, VU University Medical Center; Jan Paul De Boer, Antoni van Leeuwenhoek Hospital, Lunenburg Phase I/II Consortium, Amsterdam, the Netherlands; Stephanie Sasse, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas University, Rozzano, Milan; Pier Luigi Zinzani, University of Bologna, Bologna, Italy; John Timmerman, University of California, Los Angeles Medical Center, Los Angeles, CA; Graham P. Collins, Churchill Hospital, Oxford, United Kingdom; Radhakrishnan Ramchandren, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Jonathon B. Cohen, Emory University, Atlanta, GA; John Kuruvilla, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Kerry J. Savage, British Columbia Cancer Agency Center for Lymphoid Cancer, Vancouver, British Columbia, Canada; Marek Trneny, Charles University in Prague, General University Hospital in Prague, Prague, Czech Republic; Stephen Ansell, Mayo Clinic, Rochester, MN; and Kazunobu Kato, Benedetto Farsaci, and Anne Sumbul, Bristol-Myers Squibb, Princeton, NJ.

Authors' Reply.
J Mol Diagn 2018 Jan;20(1):125-126
Interpretation of Sequence Variants in Somatic Conditions Working Group of the Clinical Practice Committee, Association for Molecular Pathology, Bethesda, Maryland; University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.










ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma.
Am J Clin Oncol 2015 Dec;38(6):610-20
*University of Texas MD Anderson Cancer Center, Houston, TX †American Society of Clinical Oncology, Stanford Cancer Center, Stanford, CA ‡Princess Margaret Hospital, Toronto, Ontario, Canada §University of Rochester Medical Center ‡‡‡University of Rochester Medical Center, Rochester †††American Society of Clinical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY ∥American Society of Clinical Oncology, Emory University, Atlanta, GA ¶Univeristy of Texas Health Science Center at San Antonio, San Antonio, TX #University of Florida Proton Therapy Institute, Jacksonville **University of Florida, Gainesville, FL ††American Society of Clinical Oncology, St. Jude Children's Research Hospital, Memphis, TN ‡‡University of Pennsylvania Health System, Philadelphia, PA §§Yale University School of Medicine, New Haven, CT ∥∥Richard L. Roudebush VA Medical Center, Indiana University School of Medicine, Indianapolis, IN ¶¶American Society of Hematology, University of Chicago, Chicago, IL ##Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, MD ***Massachusetts General Hospital, Boston, MA.




In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
Mayo Clin Proc 2015 Aug 23;90(8):996-1000. Epub 2015 Jul 23.

Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach.
Br J Haematol 2015 Jun 29;169(5):689-93. Epub 2015 Mar 29.
Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.











Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.
Clin Cancer Res 2013 Dec 4;19(24):6882-90. Epub 2013 Oct 4.
Authors' Affiliations: Departments of Lymphoma/Myeloma, Diagnostic Imaging, and Biostatistics, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas.





High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma.
Biol Blood Marrow Transplant 2013 Jun 16;19(6):991-4. Epub 2013 Mar 16.
Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

Guidelines for the use and interpretation of assays for monitoring autophagy.
Autophagy 2012 Apr;8(4):445-544
Life Sciences Institute, University of Michigan, Ann Arbor, MI, USA.



ACR Appropriateness Criteria® Hodgkin Lymphoma-Unfavorable Clinical Stage I and II.
Am J Clin Oncol 2016 08;39(4):384-95
*Yale University School of Medicine, New Haven, CT †Memorial Sloan Kettering Cancer Center, New York, American Society of Clinical Oncology ¶University of Rochester Medical Center, Rochester, NY ‡Princess Margaret Hospital, Toronto, ON, Canada §Stanford Cancer Center, Stanford, CA, American Society of Clinical Oncology ∥University of Texas MD Anderson Cancer Center, Houston **University of Texas Health Science Center at San Antonio, San Antonio, TX #Emory University, Atlanta, GA, American Society of Clinical Oncology ††University of Florida Proton Therapy Institute, Jacksonville ‡‡University of Florida, Gainesville, FL §§St Jude Children's Research Hospital, Memphis, TN, American Society of Clinical Oncology ∥∥University of Pennsylvania Health System, Philadelphia, PA ¶¶Richard L. Roudebush VA Medical Center, Indiana University School of Medicine, Indianapolis, IN ##The University of Chicago, Chicago, IL, American Society of Hematology ***Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, MD †††Massachusetts General Hospital, Boston, MA.


ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II.
Am J Clin Oncol 2016 12;39(6):535-544
*University of Rochester Medical Center, Rochester †††Memorial Sloan Kettering Cancer Center, American Society of Clinical Oncology, New York, NY †Stanford Cancer Center, American Society of Clinical Oncology, Stanford ‡University of Southern California Keck School of Medicine, Los Angeles, CA §University of Texas MD Anderson Cancer Center, Houston ¶University of Texas Health Science Center at San Antonio, San Antonio, TX ∥Emory University, American Society of Clinical Oncology, Atlanta, GA #University of Florida Proton Therapy Institute, Jacksonville **University of Florida, Gainesville, FL ††St. Jude Children's Research Hospital, American Society of Clinical Oncology, Memphis, TN ‡‡University of Pennsylvania Health System, Philadelphia, PA §§Yale University School of Medicine, New Haven, CT ∥∥Richard L. Roudebush VA Medical Center, Indiana University School of Medicine, Indianapolis, IN ¶¶The University of Chicago, American Society of Hematology, Chicago, IL ##Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, MD ***Massachusetts General Hospital, Boston, MA.

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.
J Mol Diagn 2017 01;19(1):4-23
Interpretation of Sequence Variants in Somatic Conditions Working Group of the Clinical Practice Committee, Association for Molecular Pathology, Bethesda, Maryland; University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.



Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
N Engl J Med 2018 01 10;378(4):331-344. Epub 2017 Dec 10.
From the University of British Columbia and the Department of Medical Oncology, British Columbia Cancer Agency Centre for Lymphoid Cancer, Vancouver, Canada (J.M.C., K.J.S.); the Department of Hematology, Jagiellonian University, Krakow (W.J.), the Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw (E.L.-M.), the Department of Hematology and Transfusion Medicine, Center of Postgraduate Medical Education, Warsaw (E.L.-M.), the Department of Experimental Hematology, Medical University of Lodz, Lodz (P.S.), and the Department of Lymphoid Malignancy, the Maria Sklodowska-Curie Memorial Institute and Oncology Center, Warsaw (J.W.) - all in Poland; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (D.J.S., A.Y.); the Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN (S.M.A.); the Division of Hematology and Oncology, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea (W.S.K.); Research Innovation and Statistics, Antoine-Lacassagne Cancer Center, Nice, France (A.G.); Petrov Research Institute of Oncology, St. Petersburg, Russia (S.A.); the Department of Hematology, Faculty of Medicine, University of Debrecen, Debrecen (Á.I.), and the Department of Hematology, National Institute of Oncology, Budapest (A.R.) - both in Hungary; the Department of Advanced Biomedical Science, Federico II University Hospital, Naples (M.P.), and the Institute of Hematology Seràgnoli, University of Bologna, Bologna (P.L.Z.) - both in Italy; the Department of Lymphoma and Myeloma, M.D. Anderson Cancer Center, Houston (Y.O.); John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ (T.F.); the Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis (N.L.B.); the Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA (R.C.); the Department of Hematology-Oncology, Barbara Ann Karmanos Cancer Center, Detroit (R.R.); Gastrointestinal and Lymphoma Unit, The Royal Marsden NHS Foundation Trust, Sutton (D.C.), and the Department of Medical Oncology, University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester (J.R.) - both in the United Kingdom; the Department of Clinical Development, Seattle Genetics, Bothell, WA (N.C.J., E.S.); and Oncology Clinical Research (J.S., H.A.J., D.H.) and Global Biostatistics (R.L.), Millennium Pharmaceuticals, Cambridge, MA.

OF